Merck (MRK) on Solana

Perspective Therapeutics (NYSE: CATX) has entered a clinical collaboration and supply agreement with Merck under which Merck will provide its anti-PD-1 checkpoint inhibitor Keytruda® (pembrolizumab) at no cost for use in an ongoing Phase 1/2a study evaluating the combination with [212Pb]PSV359, Perspective's targeted alpha-particle radiopharmaceutical. The study (NCT06710756) targets FAP-α positive solid tumors, including non-small cell lung cancer and colorectal cancer, with the amendment allowing expansion cohorts to assess anti-tumor activity after the first three monotherapy dose cohorts have completed enrollment.

The rationale centers on combining radiation-driven tumor cell killing from [212Pb]PSV359 with Keytruda's immunotherapy mechanism to potentially reshape the tumor microenvironment. Perspective's Chief Medical Officer Markus Puhlmann said the approach aims to determine whether the pairing can produce synergistic effects in FAP-α expressing epithelial cancers. Keytruda is one of Merck's highest-revenue products, and the supply agreement extends its evaluation into the radiopharmaceutical combination space without disclosed financial terms.

CNBC's Jim Cramer commented on August 24 that results from Merck and Moderna's late-stage melanoma vaccine collaboration were "encouraging for both" companies. The trial pairs Moderna's personalized mRNA vaccine candidate with Merck's blockbuster cancer drug Keytruda, and Cramer cited the results while referencing his daughter's melanoma diagnosis as context for why the combined approach matters.

Keytruda remains the cornerstone of Merck's business, generating roughly 50% of the company's Q2 revenue from $16.6 billion in total sales, with Keytruda itself posting 5% growth despite years on the market. Other pipeline contributors are scaling quickly — Winrevair grew 75% year-over-year to $588 million and Welireg rose 67% to $271 million — though Merck recorded a net Q2 loss tied to $2.5 billion in generic drug headwinds.

Merck's five-year return of roughly 127% has pushed its valuation well above peers, with the stock now trading at a P/E of 116.3x against an industry average of 16.8x and a peer average of 30.3x. A tailored fair-value P/E estimate of 46.8x suggests the earnings multiple alone already signals expensive territory, and an overall value score of 2 out of 6 reinforces that view. The primary catalysts for the run are Phase 3 success for a personalized mRNA cancer vaccine developed with Moderna and sustained pipeline optimism, including excitement around Keytruda successors ahead of its eventual patent expiration.

The picture is not uniform across valuation methods. A discounted cash-flow analysis points in the opposite direction, implying the stock trades at roughly a 36% discount to intrinsic value — around \$233 per share — suggesting long-run cash generation may still justify the price. Bulls argue the stock could be 20% undervalued given biomarker-driven precision medicine accelerating pipeline productivity; bears counter that the stock may be 9% overvalued once Keytruda loss-of-exclusivity risk is fully discounted. The divergence between multiple-based and cash-flow-based frameworks underscores that at current levels, Merck leaves little room for execution missteps.

Merck (MRK) shares climbed to a 52-week high of $156.92 on August 26 after the company reported positive Phase 3 results from its INTerpath-001 melanoma trial. Wall Street interpreted the data as derisking the company's oncology platform for other tumor types, sparking analyst price target increases across multiple firms.

Argus analyst Jasper Hellweg raised his price target to $170 from $145, maintaining a Buy rating, while Wolfe Research analyst Alexandria Hammond lifted her target to $180 from $155 with an Outperform rating. Both cited Merck's strong pipeline and a string of recent regulatory approvals and clinical advances as supporting the higher valuations.

Merck has taken an equity stake in Evaxion A/S, a Danish AI-driven biotech, and licensed EVX-B3, the company's artificial intelligence-guided vaccine candidate, extending Merck's drug discovery approach into AI-powered immunology. Financial terms of the deal were not disclosed. The move marks a distinct expansion beyond Merck's existing mRNA oncology work — including its intismeran combination with KEYTRUDA, which posted Phase 3 wins in melanoma — into AI-designed preventive vaccine science.

The Evaxion partnership fits Merck's stated strategy of building more than 20 potential growth drivers to reduce reliance on KEYTRUDA ahead of its patent expiration. EVX-B3's progression through clinical trials, patient enrollment, and safety readouts will be the near-term milestones to watch as indicators of whether the AI vaccine bet translates into a meaningful pipeline asset.

Merck's personalized mRNA cancer vaccine, intismeran autogene, achieved statistically significant results in a Phase 3 trial when combined with flagship immunotherapy Keytruda, demonstrating effectiveness in preventing recurrence or metastasis in high-risk melanoma patients. The readout adds a fresh clinical catalyst to an already expanded pipeline — Merck has reportedly nearly tripled its late-phase pipeline since 2021, with commercial opportunities estimated to exceed $50 billion by the mid-2030s.

The clinical progress has contributed to MRK shares gaining roughly 40% year-to-date and nearly 79% over the past year, but the rally has sharpened a valuation debate among analysts. The consensus analyst fair value sits around $136.85, implying the stock trades roughly 9% above that level, while a DCF model cited by Simply Wall St places intrinsic value considerably higher at $232.91. Bears point to the looming Keytruda patent cliff and potential margin pressure from tariffs and drug pricing policy as risks that the current price may not fully discount.

Morgan Stanley upgraded Merck (MRK) to Overweight from Equal Weight and raised its price target to $179 from $116, implying roughly 17% upside from Wednesday's close. The upgrade came alongside the company's announcement of promising late-stage oncology trial results in partnership with Moderna, which lifted shares 13% — their best single-day gain since March 2009. Keytruda, Merck's flagship immunotherapy, generated more than $16 billion in first-half sales, and analysts noted that potential co-formulations of the drug could extend its commercial franchise beyond the upcoming 2028 patent expiration.

The analyst flagged several pipeline assets as key drivers of growth post-Keytruda: intismeran autogene and sac-TMT for oncology, and tulisokibart targeting inflammatory bowel disease. Morgan Stanley's view is that the breadth of Merck's pipeline, combined with Keytruda's sustained revenue base, gives the company multiple paths to offset the impact of biosimilar competition when exclusivity lapses.

President Trump signed an executive order on August 10, 2026 directing the administration to make individual measles, mumps, and rubella vaccines available as separate shots rather than the current combined formulation, citing unsubstantiated links to autism. The order also reorganizes the childhood immunization schedule and requires that vaccines be administered at separate medical visits. Merck, as the manufacturer of M-M-R II — the dominant licensed MMR vaccine in the United States — faces the prospect of demand disruption for its existing combined product should the order ever be implemented. Separately licensed single-antigen vaccines for measles, mumps, and rubella do not currently exist in the U.S. market, meaning Merck and any other manufacturers would face lengthy and expensive clinical trial programs to win individual FDA approvals before standalone products could be sold.

Experts and major medical groups including the American Academy of Pediatrics say the split is scientifically unwarranted and practically unlikely to materialize on a short timeline given the absence of approved products. The order carries no immediate force over state-level school vaccine mandates, which govern most immunization requirements. In the near term, the greater risk to Merck is not lost sales but reputational pressure on its core vaccine franchise and the added cost burden if regulators or policymakers eventually require development of disaggregated products. Public health officials also warn the policy could reduce vaccination adherence through added doctor visits at a time when measles cases in 2026 have already exceeded the full-year total for 2025.

Merck beat second-quarter 2026 estimates and raised its full-year revenue guidance to $66.3 billion–$67.3 billion, up from a prior range of $65.8 billion–$67 billion, driven by strong demand for newer drugs including Winrevair. The company has been actively expanding its pipeline to offset approaching generic competition for Januvia and Janumet later in 2026 and for blockbuster immunotherapy Keytruda in 2028.

At the same time, Merck cut its full-year adjusted EPS guidance sharply to $2.66–$2.76, down from prior guidance of $5.04–$5.16, primarily due to a $2.31-per-share one-time charge related to its acquisition of Terns Pharmaceuticals, which closed in May, plus roughly $0.12 per share to finance the deal and advance Terns's cancer drug candidate. The result is a mixed quarter: the underlying business is performing ahead of expectations on revenue, while the profit line reflects the near-term cost of Merck's acquisition-heavy strategy to build out its post-Keytruda portfolio.

Merck has signed royalty-free, non-exclusive licenses with seven generic manufacturers to produce its investigational once-monthly oral HIV prevention pill alimatravir across 129 low and middle-income countries — ahead of the drug completing Phase 3 trials. The early voluntary licensing approach, which targets high-burden regions including sub-Saharan Africa and Latin America, is designed to build supply chain capacity and enable rapid rollout if the drug clears regulatory approval. Partners such as Aurobindo Pharma are being positioned to pursue their own regulatory filings in covered markets.

The move marks a departure from the conventional approach of waiting until after approval to negotiate generic access deals, reflecting pressure on pharmaceutical companies to address HIV treatment gaps in resource-limited settings. With two ongoing Phase 3 trials under the EXPrESSIVE program, Merck has not yet announced regulatory filing timelines, but the pre-approval licensing infrastructure signals a commitment to broad access as a commercial and public health strategy alongside its existing HIV and oncology portfolio.